Gilenya appears to slow brain volume loss in relapsing patie
Posted: Thu May 01, 2014 2:06 am
Novartis International AG ( NVS ) announced new data showing that more patients with relapsing multiple sclerosis treated with Gilenya (fingolimod) achieved an average annual rate of brain volume loss within the range of those expected for healthy adults of a similar age vs. those patients taking placebo. People with multiple sclerosis experience shrinkage of the brain up to three to five times faster. This acceleration starts early in people with relapsing MS, even before symptoms are apparent...... Read More - http://www.ms-uk.org/gilenya